– SWITZERLAND, Geneva – ObsEva SA (NASDAQ: OBSV | SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced the appointment of Brian O’Callaghan as CEO effective 1st December 2020 succeeding Dr. Ernest Loumaye.
Brian will also be proposed for election on the Board of Directors at the next company AGM.
“The Board and myself are confident that Brian is the right person to lead ObsEva in its next phase of evolution. He is a seasoned leader with significant experience working with the public markets and delivering value to shareholders. We are delighted to welcome him as our CEO.” said Board Chair, Dr Frank Verwiel.
He added: “I would like to sincerely thank Dr. Ernest Loumaye for his steadfast leadership and commitment to ObsEva over the past seven years, developing ObsEva and its pipeline towards commercialization.”
As ObsEva evolves from a development company towards commercialization, Dr. Ernest Loumaye, co-founder and CEO of ObsEva, has expressed his wish to retire from the day to day operation. He will continue to serve as a member of ObsEva’s Board of Directors and will work to ensure a smooth transition with Brian O’Callaghan.
Dr. Ernest Loumaye, CEO and Co-Founder said: “It has been a tremendous honor to serve as the CEO of ObsEva since founding the company and I am incredibly proud of everything our team has accomplished in the past seven years. I am delighted to be succeeded by Brian whose wealth of experience will greatly benefit ObsEva as we move forward and evolve, and I am committed to supporting him and ObsEva during this transition and in the future.”
About Brian O’Callaghan
Brian O’Callaghan is a Life Science Executive who brings a breadth of experience to ObsEva, having held senior positions within several public and private pharmaceutical and biotechnology companies, in both Europe and the United States. These include CEO positions at Petra Pharma, Acucela, Sangart, and BioPartners, as well as senior management positions at Pfizer, Merck Serono, Novartis, Covance, and NPS Pharmaceuticals. Brian brings with him a wide range of experience, having managed businesses and programs across multiple therapeutic areas from concept through commercialization, and as such is well qualified to leverage his significant experience to lead ObsEva through its future development, regulatory filings, and product launches.
“I am delighted to lead ObsEva into the future as it intends to file its first market authorization application for Linzagolix for the treatment of heavy menstrual bleeding and pain associated with uterine fibroids in premenopausal women in the EU before year-end and a new drug application in the U.S. in the first half of 2021. I look forward to working with ObsEva’s Board and team to advance the development and commercialization of best in class therapies that women deserve”, said Brian O’Callaghan.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving embryo transfer outcomes following in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”.
For more information: https://www.obseva.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.